期刊文献+

罕见病医疗保障问题研究 被引量:11

Several Researches on Rare Diseases Medical Security System
下载PDF
导出
摘要 罕见病是指发病率极低的疾病,从风险特征看,罕见病风险属于不可分散性风险。罕见病保障属于社会准公共品,需要政府干预,医疗保障制度应采用以纳入国家医疗保险体系为主、财政资金救助体系为辅的组合式社会保障政策模式。 Rare diseases refer to these with extremely low incidence. The risk of rare diseases is inseparable. It needs government's intervention since their security belong to social public goods. Medical security system for rare diseases should be a combined social security policy model, which makes national health insurance system playing a main role and the financial assistance system playing a complementary role.
作者 倪沪平
出处 《中国医疗保险》 2015年第5期18-20,共3页 China Health Insurance
基金 国家社会科学基金重大项目<人口老龄化与长寿风险管理的理论和政策研究>(13&ZD163)
关键词 罕见病 保险 不可分散性风险 医疗保障制度 rare disease, insurance, the inseparable risk, medical security system
  • 相关文献

参考文献6

二级参考文献13

  • 1Ronald Baye, Lawrence O. Gostin, Bruce Jennings, et al. Public Health Ethics: Theory, Policy, And Practice[M]. Oxford:Oxford University Press, 2007.
  • 2Jams F. Childress. Public Health Ethics: Mapping the Terrain[J]. Journal of Law, Medicine and Ethics,2002, (30) : 170 - 178.
  • 3Daniel Callahan. Ethics and Public Health: Forging a Strong Relationship[J]. American Journal of Public Health,2002,92(2) : 159 - 165.
  • 4European Council. Council Recommendation of 8 June 2009 on European Action in the Field of Rare Diseases[J]. Official Journal of the European Union, 2009, C151: 7-10.
  • 5Eurordis. Eurordis Care 2: Survey of Diagnostic Delays, 8 Diseases, Europe[OL]. 2004. http://archive.eurordis.org/article.php3?id article=454.
  • 6Thamer M, Brennan N, Semansky R. A Cross-National Comparison of Orphan Drug Policies: Implications for the U.S. Orphan Drug Act[J]. Journal of Health Politics, Policy and Law, 1998, 23: 265-290.
  • 7Makoto S, Kiyohito N. Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan[J]. Drug Information Journal, 2000, 34: 839-846.
  • 8Makoto S, Kiyohito N. Development of Orphan Drugs in Japan: Effects of A Support System for Development of Orphan Drugs in Japan[J]. Drug Information Journal, 2000, 34: 829-837.
  • 9Shulman, SR, Manocchia, M. The US Orphan Drug Programme 1983-1995[J]. Pharmaco- Economics, 1997, 12: 312-326.
  • 10Shiragami M. Forefront of Orphan Drugs-Overview of Orphan Drugs Development Supporting System[J]. Dispensing Drug lnf, 1999, 5: 7.

共引文献50

同被引文献148

引证文献11

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部